Literature DB >> 8326012

Fish eye syndrome: a molecular defect in the lecithin-cholesterol acyltransferase (LCAT) gene associated with normal alpha-LCAT-specific activity. Implications for classification and prognosis.

H G Klein1, S Santamarina-Fojo, N Duverger, M Clerc, M F Dumon, J J Albers, S Marcovina, H B Brewer.   

Abstract

We have identified the molecular defect in two siblings presenting with classical clinical and biochemical features of Fish Eye disease (FED), including corneal opacities, HDL cholesterol < 10 mg/dl, normal plasma cholesteryl esters, and elevated triglycerides. In contrast to previously reported patients with FED who are unable to esterify HDL-associated cholesterol, our patients' plasma lecithin-cholesterol acetyltransferase (alpha-LCAT)-specific activities assayed using an HDL-like proteoliposome substrate were 12.7-25.7 nmol/micrograms (19.5 +/- 1.8 in controls). In addition, significant residual cholesterol esterification was present in VLDL/LDL-depleted plasma, confirming the presence of HDL-associated alpha-LCAT activity. DNA sequence analysis of the proband's LCAT gene identified deletion of the triplet coding for leu300, which resulted in the loss of a restriction site for MlnI. Digestion of PCR-amplified DNA using MlnI established that both siblings are homozygous for this defect. Expression of LCAT300-del. in human embryonic kidney-293 cells revealed normal mRNA and intracellular LCAT concentrations. However, reduced amounts of LCAT300-del., which had a normal specific alpha-LCAT activity, were present in the media. In summary, we report the first case of FED associated with a mutant enzyme that has a normal alpha-LCAT-specific activity. The functional significance of this LCAT gene defect has been established in an in vitro expression system, which demonstrates that very small amounts of this functional LCAT mutant enzyme accumulate in the media. Characterization of LCAT300-del. established that selective alpha-LCAT deficiency is not a prerequisite for the development of FED. On the basis of our combined results, we propose that the residual amounts of total plasma LCAT activity and not its distribution on lipoproteins primarily determines the heterogeneity in phenotypic expression observed in familial LCAT deficiency syndromes.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8326012      PMCID: PMC293635          DOI: 10.1172/JCI116591

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  36 in total

1.  An amino acid exchange in exon I of the human lecithin: cholesterol acyltransferase (LCAT) gene is associated with fish eye disease.

Authors:  G Skretting; H Prydz
Journal:  Biochem Biophys Res Commun       Date:  1992-01-31       Impact factor: 3.575

2.  A 'Fish-eye disease' familial condition with massive corneal opacities and hypoalphalipoproteinaemia: clinical, biochemical and genetic features.

Authors:  M Clerc; M F Dumon; D Sess; M Freneix-Clerc; M Mackness; C Conri
Journal:  Eur J Clin Invest       Date:  1991-12       Impact factor: 4.686

3.  Determination of lecithin: cholesterol acyltransfer in human blood plasma.

Authors:  K T Stokke; K R Norum
Journal:  Scand J Clin Lab Invest       Date:  1971-02       Impact factor: 1.713

4.  A dye-buoyant-density method for the detection and isolation of closed circular duplex DNA: the closed circular DNA in HeLa cells.

Authors:  R Radloff; W Bauer; J Vinograd
Journal:  Proc Natl Acad Sci U S A       Date:  1967-05       Impact factor: 11.205

5.  Prediction of protein antigenic determinants from amino acid sequences.

Authors:  T P Hopp; K R Woods
Journal:  Proc Natl Acad Sci U S A       Date:  1981-06       Impact factor: 11.205

6.  Analysis of the accuracy and implications of simple methods for predicting the secondary structure of globular proteins.

Authors:  J Garnier; D J Osguthorpe; B Robson
Journal:  J Mol Biol       Date:  1978-03-25       Impact factor: 5.469

7.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

8.  Two different allelic mutations in the lecithin:cholesterol acyltransferase (LCAT) gene resulting in classic LCAT deficiency: LCAT (tyr83-->stop) and LCAT (tyr156-->asn).

Authors:  H G Klein; P Lohse; N Duverger; J J Albers; D J Rader; L A Zech; S Santamarina-Fojo; H B Brewer
Journal:  J Lipid Res       Date:  1993-01       Impact factor: 5.922

9.  Radioimmunoassay of human plasma lecithin-cholesterol acyltransferase.

Authors:  J J Albers; J L Adolphson; C H Chen
Journal:  J Clin Invest       Date:  1981-01       Impact factor: 14.808

10.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease.

Authors:  J M Chirgwin; A E Przybyla; R J MacDonald; W J Rutter
Journal:  Biochemistry       Date:  1979-11-27       Impact factor: 3.162

View more
  15 in total

Review 1.  HDL and atherosclerotic cardiovascular disease: genetic insights into complex biology.

Authors:  Robert S Rosenson; H Bryan Brewer; Philip J Barter; Johan L M Björkegren; M John Chapman; Daniel Gaudet; Daniel Seung Kim; Eric Niesor; Kerry-Anne Rye; Frank M Sacks; Jean-Claude Tardif; Robert A Hegele
Journal:  Nat Rev Cardiol       Date:  2017-08-10       Impact factor: 32.419

2.  Overexpression of lecithin:cholesterol acyltransferase in transgenic rabbits prevents diet-induced atherosclerosis.

Authors:  J M Hoeg; S Santamarina-Fojo; A M Bérard; J F Cornhill; E E Herderick; S H Feldman; C C Haudenschild; B L Vaisman; R F Hoyt; S J Demosky; R D Kauffman; C M Hazel; S M Marcovina; H B Brewer
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

3.  Esterification of 4β-hydroxycholesterol and other oxysterols in human plasma occurs independently of LCAT.

Authors:  Daisuke Yamamuro; Hisataka Yamazaki; Jun-Ichi Osuga; Kenta Okada; Tetsuji Wakabayashi; Akihito Takei; Shoko Takei; Manabu Takahashi; Shuichi Nagashima; Adriaan G Holleboom; Masayuki Kuroda; Hideaki Bujo; Shun Ishibashi
Journal:  J Lipid Res       Date:  2020-06-19       Impact factor: 5.922

4.  A unique genetic and biochemical presentation of fish-eye disease.

Authors:  J A Kuivenhoven; E J van Voorst tot Voorst; H Wiebusch; S M Marcovina; H Funke; G Assmann; P H Pritchard; J J Kastelein
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

Review 5.  Lecithin cholesterol acyltransferase: an anti- or pro-atherogenic factor?

Authors:  Xavier Rousset; Robert Shamburek; Boris Vaisman; Marcelo Amar; Alan T Remaley
Journal:  Curr Atheroscler Rep       Date:  2011-06       Impact factor: 5.113

6.  Markedly accelerated catabolism of apolipoprotein A-II (ApoA-II) and high density lipoproteins containing ApoA-II in classic lecithin: cholesterol acyltransferase deficiency and fish-eye disease.

Authors:  D J Rader; K Ikewaki; N Duverger; H Schmidt; H Pritchard; J Frohlich; M Clerc; M F Dumon; T Fairwell; L Zech
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

Review 7.  Lecithin:cholesterol acyltransferase: old friend or foe in atherosclerosis?

Authors:  Sandra Kunnen; Miranda Van Eck
Journal:  J Lipid Res       Date:  2012-05-07       Impact factor: 5.922

Review 8.  Lecithin: cholesterol acyltransferase--from biochemistry to role in cardiovascular disease.

Authors:  Xavier Rousset; Boris Vaisman; Marcelo Amar; Amar A Sethi; Alan T Remaley
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2009-04       Impact factor: 3.243

9.  Clinical and histopathological features of a suspected case of fish-eye disease.

Authors:  Hiroko Tateno; Makoto Taomoto; Nobuo Jo; Kanji Takahashi; Yoshiko Uemura
Journal:  Jpn J Ophthalmol       Date:  2012-08-02       Impact factor: 2.447

10.  LCAT deficiency: a systematic review with the clinical and genetic description of Mexican kindred.

Authors:  Roopa Mehta; Daniel Elías-López; Alexandro J Martagón; Oscar A Pérez-Méndez; Maria Luisa Ordóñez Sánchez; Yayoi Segura; Maria Teresa Tusié; Carlos A Aguilar-Salinas
Journal:  Lipids Health Dis       Date:  2021-07-13       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.